If you want the cleanest case study of pharma and diagnostics actually operating as one strategic engine, it’s Roche. Roche ...

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a ...

FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to ...

PE: What happens post-JP Morgan Healthcare Conference? Siegall: The JP Morgan Healthcare Conference kicks off the year. A lot ...

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...

Papzimeos, an HPV-specific immunotherapy, is the first FDA-approved treatment for recurrent respiratory papillomatosis, ...

In today’s Pharmaceutical Executive Daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, ...

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

Pharmaceutical and life sciences organizations operate under extraordinary regulatory pressure. FDA, EMA, MHRA, and GxP ...